Vanucizumab ( Investigational drug (no approved brand names currently available) )

Immunotherapy

Description

Vanucizumab is an investigational immunotherapy drug currently being studied for colorectal cancer. It is a type of antibody designed to target specific proteins on the surface of certain immune cells, potentially helping the immune system recognize and attack cancer cells. In clinical trials, vanucizumab has been tested in combination with standard chemotherapy (mFOLFOX-6, which includes oxaliplatin, folinic acid, and 5-fluorouracil) for people with metastatic colorectal cancer (mCRC) that has not been previously treated. These trials compare vanucizumab to bevacizumab (Avastin), another immunotherapy drug commonly used in mCRC, both given alongside the same chemotherapy regimen. The goal of these studies is to evaluate if vanucizumab is effective and safe in this setting compared to bevacizumab.

Mechanism of Action

Vanucizumab is an antibody that targets a specific protein found on certain immune cells. By binding to this protein, it may modulate the activity of these immune cells, potentially enhancing their ability to fight cancer cells. The specific protein target and the exact mechanism by which vanucizumab affects the immune response are areas of ongoing research and characterization in clinical trials.

Side Effects

As an investigational drug The full range of side effects for vanucizumab is still being evaluated in ongoing clinical trials. The most informative trial (NCT02141295) is a Phase 2 study comparing vanucizumab to bevacizumab in combination with mFOLFOX-6. Side effects observed in this trial would be related to the combination therapy (mFOLFOX-6 + vanucizumab) and would need to be compared to those seen with mFOLFOX-6 + bevacizumab. Common side effects associated with mFOLFOX-6 include nausea Vomiting Diarrhea Fatigue And myelosuppression (low blood counts). Side effects associated with bevacizumab can include hypertension Proteinuria Bleeding And thromboembolic events. Specific side effects related to vanucizumab itself are still being determined through these studies.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT02141295 Phase 2

Archived

A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer

United States, Australia, Austria, Belgium, France, Spain, United Kingdom

Quick Info

Brand Name	Investigational drug (no approved brand names currently available)
Category	Immunotherapy
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.

Vanucizumab (** Investigational drug (no approved brand names currently available) **)